Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As with Cushing’s disease, it may be helpful to use a cortisol synthesis blocking drug while waiting for definitive treatment (18) and in cases where definitive treatment is not possible.”
From ACTH Antagonists (2016) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Once a diagnosis is conclusively made, the optimal treatment is surgical removal of the tumor – ideally preserving the remaining pituitary function.”
From ACTH Antagonists (2016) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“excess cortisol secretion by unilateral adrenocortical tumors or by bilateral adrenal hyperplasia or dysplasia (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884 · cited 1×
“However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Ilias, I., Torpy, D. J., Pacak, K., Mullen, N., Wesley, R. A., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2527 · Cited by 713
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Isidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationThe hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment
Lindsay, J. R., & Nieman, L. K. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0025 · Cited by 449 · cited 1×
“Detection of Cushing’s syndrome usually occurs late in gestation, and the diagnosis is complicated by the signs of normal pregnancy, such as central weight gain, facial plethora, and pigmentation (101) and the normal physiological changes in the maternal HPA axis.”
BackgroundSelf-citationPosterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Self-citationRisk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413 · cited 1×
“The risk of second tumor formation after pituitary radiation is considered to be in the range of 1–2% (39), but this may not be due to the radiotherapy per se.”
Background
Research works printed but not linked: 1
- 52. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F 1986 Prolonged - treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14:485-486
Cited by
Items 101–200 of 863
Castinetti, F., Morange, I., Conte‐Devolx, B., & Brue, T. C. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-41 · Cited by 88
“Pregnancy is forbidden during mitotane therapy and for two years after drug withdrawal due to teratogenic effects [41,58,59].”
BackgroundNonfunctioning pituitary tumors
Molitch, M. E. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00012-5 · Cited by 73
“Therefore, prolactinomas would generally be treated with dopamine agonists and those producing GH or ACTH would be treated with surgery (Biller et al., 2008; Melmed et al., 2009, 2011).”
BackgroundGlucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
He, X., Findling, J. W., & Auchus, R. J. (2022) · Pituitary · doi:10.1007/s11102-022-01218-y · Cited by 64
Lila, A. R., Gopal, R. A., Acharya, S. V., George, J., Sarathi, V., Bandgar, T., Menon, P. S., & Shah, N. S. (2010) · Endocrine Practice · doi:10.4158/ep10031.or · Cited by 72
Ben-Shlomo, A., Schmid, H., Wawrowsky, K., Pichurin, O., Hubina, E., Chesnokova, V., Liu, N.-A., Culler, M., & Melmed, S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1311 · Cited by 73
Self-citationManaging Cushing’s disease: the state of the art
Colao, A., Boscaro, M., Ferone, D., & Casanueva, F. F. (2014) · Endocrine · doi:10.1007/s12020-013-0129-2 · Cited by 74
Self-citationSwearingen, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3237 · Cited by 71
Self-citationClinical features and management of ectopic ACTH syndrome at a single institute in Japan
Doi, M., Sugiyama, T., Izumiyama, H., Yoshimoto, T., & Hirata, Y. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-265 · Cited by 69
Gentilin, E., Tagliati, F., Filieri, C., Molè, D., Minoia, M., Ambrosio, M. R., Uberti, E. C. D., & Zatelli, M. C. (2013) · Endocrinology · doi:10.1210/en.2012-2070 · Cited by 69
Assessment of health surveys: fitting a multidimensional graded response model
Depaoli, S. A., Tiemensma, J., & Felt, J. M. (2018) · Psychology Health & Medicine · doi:10.1080/13548506.2018.1447136 · Cited by 80
“Treatment for CS depends on the cause of the hypercortisolism but includes transsphenoidal surgery, adrenalectomy, pituitary irradiation, or a gradual reduction in the dosage of glucocorticoid steroids (Biller et al., 2008; Nieman & Ilias, 2005; Sharma, Nieman, & Feelders, 2015).”
BackgroundFleseriu, M., Hamrahian, A. H., Hoffman, A. R., Kelly, D. F., & Katznelson, L. (2016) · Endocrine Practice · doi:10.4158/ep161512.dscr · Cited by 68
Efficacy of medical treatment in Cushing's disease: a systematic review
Gadelha, M. R., & Vieira Neto, L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12345 · Cited by 66
Biochemical Predictors of Outcome of Pituitary Surgery for Cushing’s Disease
Alwani, R. A., de Herder, W. W., van Aken, M. O., van den Berge, J. H., Delwel, E. J., Dallenga, A. H. G., De Jong, F. H., Lamberts, S. W. J., van der Lely, A. J., & Feelders, R. A. (2010) · Neuroendocrinology · doi:10.1159/000258677 · Cited by 66
Cébula, H., Baussart, B., Villa, C., Assié, G., Boulin, A., Foubert, L., Aldéa, S., Bennis, S., Bernier, M., Proust, F., et al. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-017-3140-1 · Cited by 69
Liu, Y., Liu, X.-H., Hong, X., Liu, P., Bao, X., Yao, Y., Xing, B., Yan-sheng, L., Huang, Y., Zhu, H., et al. (2019) · Neuroendocrinology · doi:10.1159/000496753 · Cited by 73
Treatment of Cushing disease: overview and recent findings
Giustina, A. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12952 · Cited by 66
“So far, there is no significant experience reported with the glucocorticoid receptor antagonist mifepristone (RU 486) in CD, and assessment of its efficacy in the absence of a biochemical marker is challenging.(9) In a European retrospective study, clinical signs of hypercortisolism improved rapidly in three of four p…”
InfluentialPostoperative Testing to Predict Recurrent Cushing Disease in Children
Batista, D. L., Oldfield, E. H., Keil, M. F., & Stratakis, C. A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0302 · Cited by 66
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
“Once the diagnosis of CD has been confirmed, selective tumorectomy via TSS is the treatment of choice for a majority of CD patients, associated with a complete remission rate of 60%–90% and <65% for micro-tumors and macro-tumors, respectively [65,140].”
BackgroundMethodInfluentialKorbonits, M., Blair, J., Bogusławska, A., Ayuk, J., Davies, J. H., Druce, M. R., Evanson, J., Flanagan, D., Glynn, N., Higham, C., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00949-7 · Cited by 71
“However, selective microadenomectomy can be technically very difficult in children and surgeon experience is a predictor of success 102,105 .”
InfluentialFleseriu, M., Molitch, M. E., Gross, C., SCHTEINGART, D. E., Vaughan, T. B., & Biller, B. M. K. (2013) · Endocrine Practice · doi:10.4158/ep12149.ra · Cited by 66
Self-citationHuang, W., & Molitch, M. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.004 · Cited by 66
Monteith, S. J., Starke, R. M., Jane, J. A., & Oldfield, E. H. (2012) · Journal of Neurosurgery · doi:10.3171/2011.12.jns11886 · Cited by 65
Webb, S. M., Mo, D., Lamberts, S. W. J., Melmed, S., Cavagnini, F., Pecori Giraldi, F., Strasburger, C. J., Zimmermann, A. G., Woodmansee, W. W., & on behalf of the International HypoCCS Advisory Board (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0806 · Cited by 64
Self-citationSchopohl, J., Gu, F., Rubens, R., Van Gaal, L., Bertherat, J., Ligueros-Saylan, M., Trovato, A., Hughes, G., Salgado, L. R., Boscaro, M., et al. (2015) · Pituitary · doi:10.1007/s11102-014-0618-1 · Cited by 63
“Cushing’s disease is a rare and debilitating disorder of hypercortisolism caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor [1–3].”
BackgroundSelf-citationWoodmansee, W. W., Carmichael, J. D., Kelly, D. F., & Katznelson, L. J. (2015) · Endocrine Practice · doi:10.4158/ep14541.dscr · Cited by 69
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease
Lu, J., Chatain, G. P., Bugarini, A., Wang, X., Maric, D., Walbridge, S., Zhuang, Z., & Chittiboina, P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00464 · Cited by 65
Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone
Castinetti, F., Conte‐Devolx, B., & Brue, T. C. (2010) · Neuroendocrinology · doi:10.1159/000314224 · Cited by 71
“Cushing’s syndrome can be caused by adrenal, pituitary or ectopic tumors. Surgery remains the first-line treatment, and can be followed by pituitary irradiation or bilateral adrenalectomy if necessary. Medical management remains, however, of major interest when surgery is impossible, in preparation for surgery, or whe…”
BackgroundWagenmakers, M. A. E. M., Netea‐Maier, R. T., Van Lindert, E. J., Timmers, H. J. L. M., Grotenhuis, J. A., & Hermus, A. R. M. M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03334.x · Cited by 63
Self-citationHonegger, J., Schmalisch, K., Beuschlein, F., Kaufmann, S., Schnauder, G., Naegele, T., & Psaras, T. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04268.x · Cited by 61
MANAGEMENT OF ENDOCRINE DISEASE: Paediatric Cushing's disease
Storr, H. L., & Savage, M. O. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0013 · Cited by 62
Biller, B. M. K., Colao, A., Petersenn, S., Bonert, V. S., & Boscaro, M. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-10 · Cited by 61
Self-citationBurman, P., Engström, B. E., Ekman, B., Karlsson, F. A., Schwarcz, E., & Wahlberg, J. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0807 · Cited by 59
Electrolyte disorders in cancer patients: a systematic review
Berardi, R., Torniai, M., Lenci, E., Pecci, F., Morgese, F., & Rinaldi, S. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.008 · Cited by 72
“Other treatment options, such as steroid-synthesis inhibitors (metyrapone, mitotane, trilostane, ketoconazole, and aminoglutethimide) and glucocorticoid receptor antagonists (mifepristone), are available to control severe hypercortisolemia([138]).”
BackgroundPaediatric Pituitary Adenomas: A Decade of Change
Guaraldi, F., Storr, H. L., Ghizzoni, L., Ghigo, E., & Savage, M. O. (2014) · Hormone Research in Paediatrics · doi:10.1159/000357673 · Cited by 58
Mifepristone for Management of Cushing's Syndrome
Morgan, F. H., & Laufgraben, M. J. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1202 · Cited by 54
Ménard, J., Rigel, D. F., Watson, C. E., Jeng, A. Y., Fu, F., Beil, M. E., Liu, J., Chen, W., Hu, C.-W., Leung-Chu, J., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0340-9 · Cited by 61
“Indeed, LCI699 has low pharmacokinetic variability, and may avoid the limitations of metyrapone and other steroidogenesis inhibitors such as ketoconazole and mitotane [49].”
BackgroundValassi, E., Franz, H., Brue, T., Feelders, R. A., Netea-Maier, R., Tsagarakis, S., Webb, S. M., Yaneva, M., Reincke, M., Droste, M., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0997 · Cited by 58
Self-citationCostenaro, F., Rodrigues, T. C., Rollin, G. A. F., Ferreira, N. P., & Czepielewski, M. A. (2014) · Clinical Endocrinology · doi:10.1111/cen.12300 · Cited by 56
Dabrh, A. M. A., Ospina, N. S., Nofal, A. A., Farah, W. H., Barrionuevo, P., Sarigianni, M., Mohabbat, A. B., Benkhadra, K., Leon, B. G. C., Gionfriddo, M. R., et al. (2016) · Endocrine Practice · doi:10.4158/ep15922.ra · Cited by 65
Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide
Varlamov, E. V., Han, A. J., & Fleseriu, M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101490 · Cited by 60
Treatment of Cushing's disease: a mechanistic update
Cuevas-Ramos, D., & Fleseriu, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0300 · Cited by 54
“(2006), Biller et al. (2008), Be”
Schumacher, C., Steele, R. E., & Brunner, H. R. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328363570c · Cited by 59
“The unselective steroidogenesis inhibitor metyrapone, used for Cushing’s disease, has been reported to increase 11-deoxycorticosterone levels, and this has been associated with BP increases and the occurrence of hypokalemia [22,23].”
BackgroundMedical therapy of pituitary adenomas: Effects on tumor shrinkage
Colao, A., Pivonello, R., Somma, C. D., Savastano, S., Grasso, L. F. S., & Lombardi, G. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9107-z · Cited by 62
Self-citationBou Khalil, R., Baudry, C., Guignat, L., Carrasco, C., Guibourdenche, J., Gaillard, S., Bertagna, X., & Bertherat, J. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0424 · Cited by 58
Self-citationKeil, M. F., Merke, D. P., Gandhi, R., Wiggs, E. A., Obunse, K., & Stratakis, C. A. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03515.x · Cited by 58
The Role of Isotretinoin Therapy for Cushing’s Disease: Results of a Prospective Study
Vilar, L., Albuquerque, J. L., Lyra, R., Trovão Diniz, E., Rangel Filho, F., Gadelha, P., Thé, A. C., Ibiapina, G. R., Gomes, B. S., Santos, V., et al. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8173182 · Cited by 54
Ragnarsson, O., & Johannsson, G. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0534 · Cited by 51
Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
Hinojosa‐Amaya, J. M., Ramos, D. C., & Fleseriu, M. (2019) · Drugs · doi:10.1007/s40265-019-01128-7 · Cited by 57
Erickson, D. Z., Erickson, B. J., Watson, R. E., Patton, A. C., Atkinson, J. L. D., Meyer, F. B., Nippoldt, T. B., Carpenter, P. C., Natt, N., Vella, A. V., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03723.x · Cited by 53
Cushing's disease: predicting long-term remission after surgical treatment
Pendharkar, A. V., Sussman, E. S., Ho, A. L., Hayden Gephart, M. G., & Katznelson, L. (2015) · Neurosurgical Focus · doi:10.3171/2014.10.focus14682 · Cited by 51
Cushing's disease: a multidisciplinary overview of the clinical features, diagnosis, and treatment.
Buliman, A., Tătăranu, L. G., Păun, D. L., Mirică, A., & Dumitrache, C. (2016) · PubMed Central · Cited by 73
Genetic mechanisms of human hypertension and their implications for blood pressure physiology
Seidel, E., & Scholl, U. I. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00032.2017 · Cited by 60
Potential utility of FLAIR in MRI-negative Cushing’s disease
Chatain, G. P., Patronas, N., Smirniotopoulos, J. G., Piazza, M., Benzo, S., Ray-Chaudhury, A., Sharma, S., Lodish, M., Nieman, L., Stratakis, C. A., et al. (2018) · Journal of Neurosurgery · doi:10.3171/2017.4.jns17234 · Cited by 48
Self-citationSistema endocrino y corazón: una revisión
Rhee, S. S., & Pearce, E. N. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2010.10.015 · Cited by 56
“Medical control of hypercortisolism in nonsurgical patients may be achieved using ketoconazole, metyrapone, and/or mitotane.(50)”
Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A. B., Petersenn, S., Schopohl, J., Snyder, P., Hughes, G., Trovato, A., et al. (2014) · Pituitary · doi:10.1007/s11102-013-0503-3 · Cited by 51
Self-citationSimeoli, C., Auriemma, R. S., Tortora, F., Leo, M. D., Iacuaniello, D., Cozzolino, A., Martino, M. C. D., Pivonello, C., Mainolfi, C. G., Rossi, R., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0557-2 · Cited by 53
Self-citationvan der Pas, R., Feelders, R. A., Gatto, F., de Bruin, C., Pereira, A. M., van Koetsveld, P. M., Sprij-Mooij, D. M., Waaijers, A. M., Dogan, F., Schulz, S., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1987 · Cited by 51
Self-citationMel'nichenko, G. A., Dedov, I. I., Belaya, Z. E., Rozhinskaya, L. Y., Vagapova, G. R., Волкова, Н. И., Grigor’ev, A. Y., Grineva, E. N., Marova, E. I., Mkrtumayn, A. M., et al. (2015) · Problems of Endocrinology · doi:10.14341/probl201561255-77 · Cited by 62
Ramsey, I. K. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2009.10.008 · Cited by 51
Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications
Martino, M. C. D., Hofland, L. J., & Lamberts, S. W. J. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82011-4 · Cited by 50
Self-citationThe use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome
Castinetti, F., Brue, T., & Conte-Devolx, B. (2012) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835430bf · Cited by 51
Clark, A. J., Forfar, R., Hussain, M., Jerman, J., McIver, E., Taylor, D., & Chan, L. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00101 · Cited by 49
“Surgery for Cushing’s disease requires extensive experience and skill and is normally undertaken in specialist centers (18).”
BackgroundInfluentialBoronat, M., Marrero, D., López-Plasencia, Y., Barber, M. Á., Schamann, Y., & Novoa, F. J. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.521268 · Cited by 49
“A general consensus exists that, if medical treatment for Cushing’s syndrome is necessary during pregnancy, ketoconazole is not indicated, and metyrapone, for which there is a wider experience, should be used instead [1,2].”
BackgroundEGFR Induces E2F1-Mediated Corticotroph Tumorigenesis
Araki, T., Liu, X., Kameda, H., Tone, Y., Fukuoka, H., Tone, M., & Melmed, S. K. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1053 · Cited by 48
Self-citationMortality in Patients with Endogenous Cushing’s Syndrome
Javanmard, P., Duan, D., & Geer, E. B. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.005 · Cited by 46
Gamma knife radiosurgery for Cushing’s disease and Nelson’s syndrome
Marek, J., Ježková, J., Hána, V., Kršek, M., Liščák, R., Vladyka, V., & Pecen, L. (2014) · Pituitary · doi:10.1007/s11102-014-0584-7 · Cited by 47
Storr, H. L., Drake, W. M., Evanson, J., Matson, M. B., Berney, D. M., Grossman, A. B., Akker, S. A., Monson, J. P., Alusi, G., Savage, M. O., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12275 · Cited by 50
Self-citationUpdate on medical treatment for Cushing’s disease
Ramos, D. C., Lim, D. S. T., & Fleseriu, M. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0033-9 · Cited by 49
“therapies in persistent hypercortisolism [3, 11, 13], medical treatment now plays an increasingly important role in CD management [7, 10, 14].”
BackgroundFeng, M., Liu, Z., Liu, X., Bao, X., Yao, Y., Deng, K., Xing, B., Lian, W., Zhu, H., Lü, L., et al. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.09.105 · Cited by 50
Dopamine Agonists for Pituitary Adenomas
Cooper, O. B., & Greenman, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00469 · Cited by 47
Tritos, N. A., & Biller, B. M. K. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00015-0 · Cited by 51
Self-citationPennacchietti, V., Garzaro, M., Grottoli, S., Pacca, P., Garbossa, D., Ducati, A., & Zenga, F. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.01.049 · Cited by 46
“Concerning functioning pituitary adenomas treated i n our series, biochemical remission for ACTHsecreting tumors was diagnosed at 3 months post-ope ratively, with hypocortisolemia, low or normal 24-hours urinary free cortisol or salivary cortisol and/or cortisol suppression < 1,8 μg/dl after 1 mg dexamethasone (2), (8…”
BackgroundHealth Care Resource Use and Costs Among Patients with Cushing Disease
Swearingen, B., Wu, N., Chen, S., Pulgar, S. J., & Biller, B. M. K. (2011) · Endocrine Practice · doi:10.4158/ep10368.or · Cited by 47
Self-citationHypercoagulable state in C ushing's syndrome is reversible following remission
Kaštelan, D., Dušek, T., Kraljević, I., & Aganović, I. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04479.x · Cited by 45
Sun, Y., Fang, M., Davies, H., & Hu, Z. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.856410 · Cited by 45
“as a second-line or third-line therapy for the patients, who have failed to achieve remission with other treatment modalities [5,34].”
Wilson, P. J., Williams, J. R., & Smee, R. I. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.04.007 · Cited by 47
FKBP5 mRNA Expression Is a Biomarker for GR Antagonism
Bali, U., Phillips, T., Hunt, H., & Unitt, J. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1624 · Cited by 50
Stewart, P. M., & Krone, N. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00015-8 · Cited by 61
Self-citationFan, Y., Liu, Z., Hou, B., Li, L., Liu, X.-H., Liu, Z., Wang, R., Lin, Y., Feng, F., Tian, J., et al. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.108647 · Cited by 45
Clinicopathological correlates of adrenal Cushing's syndrome
Duan, K., Hernandez, K., & Mete, Ö. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202612 · Cited by 48
Morris, L. F., Harris, R., Milton, D. R., Waguespack, S. G., Habra, M. A., Jiménez, C., Vassilopoulou‐Sellin, R., Lee, J. E., Perrier, N. D., & Grubbs, E. G. (2013) · Surgery · doi:10.1016/j.surg.2013.06.017 · Cited by 45
New developments in the medical treatment of Cushing's syndrome
van der Pas, R., de Herder, W. W., Hofland, L. J., & Feelders, R. A. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0191 · Cited by 42
Self-citationThe New Genetic Landscape of Cushing’s Disease: Deubiquitinases in the Spotlight
Sbiera, S., Kunz, M., Weigand, I., Deutschbein, T., Dandekar, T., & Faßnacht, M. (2019) · Cancers · doi:10.3390/cancers11111761 · Cited by 45
“Surgical resection results in remission in 65–90% of patients [4,5] but in case of persistent or recurrent disease therapeutic options are limited.”
BackgroundManagement of Cushing syndrome in children and adolescents: experience of a single tertiary centre
Güemes, M., Murray, P. G., Brain, C. E., Spoudeas, H. A., Peters, C. J., Hindmarsh, P. C., & Dattani, M. (2016) · European Journal of Pediatrics · doi:10.1007/s00431-016-2727-5 · Cited by 44
Pivonello, R., Arnaldi, G., Scaroni, C. M., Giordano, C. S. D. S., Cannavò, S., Iacuaniello, D., Trementino, L., Zilio, M., Guarnotta, V., Albani, A., et al. (2019) · Endocrine · doi:10.1007/s12020-018-1818-7 · Cited by 46
Self-citationFleseriu, M., Petersenn, S., Biller, B. M. K., Kadıoğlu, P., Block, C. E. M. D., T'Sjoen, G. G., Vantyghem, M., Tauchmanovà, L., Wojna, J., Roughton, M., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14081 · Cited by 46
Self-citationBaroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
“The use of these drugs is limited because of variable efficacy and important side effects [126].”
BackgroundPituitary Radiotherapy for Cushing’s Disease
Losa, M., Picozzi, P., Redaelli, M. G., Laurenzi, A., & Mortini, P. (2010) · Neuroendocrinology · doi:10.1159/000314299 · Cited by 41
Donadille, B., Groussin, L., Waintrop, C., Abbas, H., Tenenbaum, F., Dugué, M.-A., Coste, J., Bertagna, X., & Bertherat, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1317 · Cited by 42
Self-citationDimopoulou, C., Ising, M., Pfister, H., Schopohl, J., Stalla, G. K., & Sievers, C. (2012) · Neuroendocrinology · doi:10.1159/000338408 · Cited by 41
Self-citationCastro, M. A., Corrales, E. P., Millán, J. M. S., Rebolleda, G., Pian, H. G., Ruz‐Caracuel, I., Santos, G. D. L., Urzaiz, L. L., Escobar-Morreale, H. F., & Berrocal, V. R. (2020) · Endocrine · doi:10.1007/s12020-020-02247-y · Cited by 43
“Levels above normal range indicate tumor persistence [72, 84, 85].”
BackgroundPerioperative Management of a Patient With Cushing Disease
Varlamov, E. V., Vila, G., & Fleseriu, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac010 · Cited by 41
“A cortisol nadir of 2 to 5 μg/dL (55-138 nmol/L) has also been considered as remission in many studies; the likelihood of recurrence appears to be similar in most studies to that of patients with cortisol of less than 2 μg/dL (10% in the long term in some studies) [81, 88, 89].”
BackgroundQuality of Life and Other Outcomes in Children Treated for Cushing Syndrome
Keil, M. F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1123 · Cited by 45
Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome
Santos, A., Resmini, E., Gómez-Ansón, B., Crespo, I., Granell, E., Valassi, E., Pires, P., Vives-Gilabert, Y., Martínez-Momblán, M. A., de Juan, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0600 · Cited by 37
Castaño-León, A. M., Paredes, I., Munarriz, P. M., Roldan, L. J., Hilario, A., Calatayud, M., Hernández‐Laín, A., Garcia, E. G., Fernández, A. G., Lagares, A., et al. (2019) · Neurosurgery · doi:10.1093/neuros/nyz201 · Cited by 40
Fan, Y., Li, Y., Bao, X., Zhu, H., Lü, L., Yao, Y., Li, Y., Su, M., Feng, F., Feng, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa698 · Cited by 45
New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome
Senanayake, R., Gillett, D., MacFarlane, J., van der Meulen, M., Powlson, A., Koulouri, O., Casey, R. T., Bashari, W. A., & Gurnell, M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101513 · Cited by 40
Danet‐Lamasou, M., Asselineau, J., Perez, P., Vivot, A., Nunes, M., Loiseau, H., San‐Galli, F., Cherifi‐Gatta, B., Corcuff, J., & Tabarin, A. (2015) · Clinical Endocrinology · doi:10.1111/cen.12534 · Cited by 39
Automatic Face Classification of Cushing's Syndrome in Women - A Novel Screening Approach
Kosilek, R. P., Schopohl, J., Grünke, M., Reincke, M., Dimopoulou, C., Stalla, G. K., Würtz, R. P., Lammert, A., Günther, M., & Schneider, H. (2013) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0033-1349124 · Cited by 39
Self-citationMedical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide
Pedroncelli, A. M. (2010) · Neuroendocrinology · doi:10.1159/000314352 · Cited by 39
Metadata
- Authors
- Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., Klibanski, A., Lacroix, A., Lindsay, J. R., Newell-Price, J., Nieman, L. K., Petersenn, S., Sonino, N., Stalla, G. K., Swearingen, B., Vance, M. L., Wass, J. A. H., & Boscaro, M.
- Affiliations
- Massachusetts General Hospital (US)
- St Bartholomew's Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Cedars-Sinai Medical Center (US)
- Hôpital Cochin (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Naples Federico II (IT)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Altnagelvin Area Hospital (GB)
- University of Sheffield (GB)
- National Institutes of Health (US)
- University of Duisburg-Essen (DE)
- University of Padua (IT)
- Max Planck Institute of Psychiatry (DE)
- University of Virginia Health System (US)
- Churchill Hospital (GB)
- Marche Polytechnic University (IT)
- Corresponding author
- Boscaro, M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2454-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3214276
- OpenAlex
- W2147573461
- Cited by
- 853
- References
- 107
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 40 · 2021: 35 · 2020: 47 · 2019: 59 · 2018: 42 · 2017: 40 · 2016: 44 · 2015: 91 · 2014: 69 · 2013: 74 · 2012: 70
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- ACTH-dependent Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, Nelson's syndrome, transsphenoidal surgery, pituitary tumor resection, radiotherapy, medical therapy, bilateral adrenalectomy, remission criteria, consensus statement
- MeSH terms
- ACTH Syndrome, Ectopic, Adrenal Insufficiency, Adrenalectomy, Adrenocorticotropic Hormone, Cushing Syndrome, Humans, Hypophysectomy, Metyrapone, Mitotane, Nelson Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.